Cogent Biosciences, Inc. COGT 深 沪
等待开盘 04-02 09:30:00 美东时间
35.24
-3.250
-8.44%
华盛通- 最 高38.00
- 今 开37.665
- 成交量 861.88万股
- 最 低 34.345
- 昨 收 38.49
- 总市值 57.20亿
- 52周最高 43.73
- 市盈率 静 --
- 换手率 5.31%
- 52周最低 4.115
- 委 比 -11.24%
- 总股本 1.62亿
- 历史最高 43.73
- 量 比 3.84
- 振 幅 9.50%
- 历史最低 3.67
- 每 手 1
- 风险率 13.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug
04-01 20:06
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Cogent Biosciences shares are trading higher after the company announced that the FDA approved its new drug application for bezuclastinib in patients with nonAdvanced systemic mastocytosis.
Cogent Biosciences shares are trading higher after the company announced that t...
03-16 21:03
Reported Saturday, Cogent Biosciences Highlights SUMMIT Data At AAAAI 2026, Bezuclastinib Delivers –32.0 Point Mean TSS Reduction At 48 Weeks With 99% Achieving ≥50% Serum Tryptase Reduction
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with
03-02 15:51
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
02-18 20:29
Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.97 percent. This is a 577.78 percent decrease over losses of $(0.09) per share
02-18 05:58
财报速睇 | Cogent Biosciences, Inc. 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损1.02亿美元，同比亏损扩大50.9%
华盛资讯2月18日讯，Cogent Biosciences, Inc.公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损1.02亿美元，同比亏损扩大50.9%。
02-18 02:19
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
01-21 21:54
